Natera, Inc. (NTRA)
NASDAQ · Healthcare · Medical - Diagnostics & Research
Profile
Natera, Inc.
- Exchange
- NASDAQ
- Ticker
- NTRA
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Country
- US
Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.
Key facts
Natera, Inc.: key facts
- Natera, Inc. (NASDAQ: NTRA) is a Medical - Diagnostics & Research company in the Healthcare sector.
- In fiscal 2025, Natera, Inc. reported revenue of $2.3B and net income of -$208.2M.
- Revenue grew 38.6% a year over the last 4 fiscal years.
- Free cash flow was positive in 2 of the last 5 fiscal years.
- Net income was positive in 0 of the last 5 fiscal years.
- Over the last twelve months, revenue was $2.7B and net income was -$192.3M.
MonkScore
Natera, Inc.'s MonkScore
MonkScore
MonkScore range: 70–80
as of October 2026
Sector rank: 208 of 628 in Healthcare
How this score is madeDisclaimer
Pillar ranges
- Growth70–80
- Profitability20–30
- Quality40–50
- Market Conviction90–100
- Safety70–80
The MonkScore runs from 0 to 100. Each range is one of ten 10-point groups, from 0–10 to 90–100.
Each pillar's range uses the same ten groups. The exact score and the pillar scores are in the MonkStreet app.
Fundamentals
Figures from the statements
Natera, Inc.'s annual figures and the last twelve months, in USD. Last report: 30 June 2026.
| Figure | Last 12 months | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Revenue | $2.7B | $2.3B | $1.7B | $1.1B | $820.2M | $625.5M |
| Gross profit | $1.8B | $1.5B | $1.0B | $492.7M | $364.0M | $307.1M |
| Operating income | -$289.7M | -$309.9M | -$222.3M | -$446.2M | -$541.0M | -$468.2M |
| Net income | -$192.3M | -$208.2M | -$190.4M | -$434.8M | -$547.8M | -$471.7M |
| Operating cash flow | $228.2M | $215.3M | $135.7M | -$247.0M | -$431.5M | -$335.2M |
| Capital expenditure | -$156.5M | -$106.2M | -$66.4M | -$39.2M | -$47.7M | -$41.0M |
| Free cash flow | $71.7M | $109.1M | $69.2M | -$286.2M | -$479.2M | -$376.3M |
| Total debt | $238.5M | $214.4M | $187.1M | $442.0M | $446.2M | $397.2M |
| Cash | $1.1B | $1.1B | $945.6M | $642.1M | $466.1M | $84.4M |
Revenue growth a year
- 1-year
- 35.9%
- 3-year
- 41.1%
- 4-year
- 38.6%
Compound growth between fiscal years.
Peers
Similar companies
- Quest Diagnostics IncorporatedNYSE:DGXMonkScore range: 70–80
- Sotera Health CompanyNASDAQ:SHCMonkScore range: 70–80
- IQVIA Holdings Inc.NYSE:IQVMonkScore range: 70–80
- Agilent Technologies, Inc.NYSE:AMonkScore range: 70–80
- Mettler-Toledo International Inc.NYSE:MTDMonkScore range: 90–100
- Illumina, Inc.NASDAQ:ILMNMonkScore range: 90–100
- CareDx, IncNASDAQ:CDNAMonkScore range: 90–100
- Medpace Holdings, Inc.NASDAQ:MEDPMonkScore range: 90–100
Compare
Compare with
Score my top stocks · 14-day free trial · card required · not charged during the trial · cancel in one click
MonkStreet provides research, not investment advice.
Page built on 31 October 2026.